All news

4 November 2026

Novo Nordisk's Wegovy pill beats forecasts, and the company raises its outlook again

The Danish drugmaker's third-quarter sales and profit topped analyst estimates, led by its new weight-loss pill, and it now expects roughly flat results for 2026.

Novo Nordisk, the Danish company behind Ozempic and Wegovy, has had a rough couple of years watching rival Eli Lilly overtake it in the US weight-loss market. On Wednesday it had some better news: third-quarter results came in ahead of forecasts, helped by a strong start for its Wegovy pill, and it raised its full-year outlook. Its shares rose as much as 6% in early trading.

What happened

  • Sales were 79.2 billion Danish kroner, about $11.9 billion, up 4% from a year earlier at constant exchange rates (stripping out currency swings). Analysts polled by FactSet expected 73.6 billion kroner.
  • Adjusted operating profit, the profit from the core business before interest and tax, was 31.7 billion kroner versus 28.6 billion expected.
  • The Wegovy pill, launched earlier this year, sold 5.4 billion kroner, against roughly 4.5 billion expected. Injectable Wegovy brought in 20.4 billion and Ozempic 29.7 billion, both also above forecasts.
  • Novo now sees 2026 adjusted sales and operating profit growth between minus 2% and plus 2% at constant currency, up from minus 6% to flat before.

Novo also said CFO Karsten Munk Knudsen will leave at the end of 2026 after 27 years at the company. He will be replaced by Luigi La Corte, currently CFO of Swiss skin-care company Galderma.

Why it matters

GLP-1 drugs, the class of medicines that includes Wegovy and Lilly's Zepbound, are now used by about 10% of Americans, and the US is by far the biggest market. CEO Mike Doustdar told CNBC that Novo's products still have 80% market share despite tougher competition. Moving guidance from shrinking a bit to roughly flat is progress, though cheering for zero growth is a sign of how hard the past year has been.

The pill matters because many people would rather swallow a tablet than inject themselves. Lilly's rival pill, Foundayo, missed analyst forecasts last quarter, even though Lilly said its US prescriptions doubled from the previous quarter.

Not everyone is convinced the turnaround is complete. Citi kept a neutral rating on Novo after the results, pointing to uncertainty over future drug pricing and no clear successor to Wegovy. Doustdar himself said one good quarter does not make a recovery. Novo's Copenhagen shares were still down about 13% for the year after Wednesday's move.

What to watch

  • The launch of CagriSema, Novo's next-generation combination drug, which analysts have questioned after it failed to beat Lilly's medicines already on the market.
  • Whether next-generation weight-loss drugs can also treat obesity-linked conditions such as heart and kidney disease, sleep apnea and arthritis.
  • US pricing pressure on GLP-1 drugs.

Novo's US-listed shares (ADRs) and filings are on its Noorult company page.

The companies in this story

Based on reporting by CNBC: Novo shares jump as Wegovy pill sales impress, drugmaker hikes outlook. Facts, not advice.

More news